Core Insights - The SURMOUNT-5 study results indicate that tirzepatide demonstrates superior efficacy in weight loss compared to semaglutide, achieving significant weight reduction in participants [1][2] Group 1: Study Results - Tirzepatide achieved a relative weight loss of 1.47 times compared to semaglutide, with an average weight reduction of 20.2% versus 13.7% for semaglutide at week 72 [1] - Participants in the tirzepatide group lost an average of 22.8 kg, while those in the semaglutide group lost an average of 15.0 kg [1] - In key secondary endpoints, 64.6% of participants in the tirzepatide group achieved a weight loss of ≥15%, compared to 40.1% in the semaglutide group [2] Group 2: Safety and Tolerability - The overall safety profile of tirzepatide was consistent with previous SURMOUNT studies, with the most common adverse events being mild to moderate gastrointestinal issues [2] - The proportion of participants who discontinued treatment due to adverse events was 6.1% for tirzepatide and 8% for semaglutide, although the study could not directly compare safety and tolerability between the two drugs [2] Group 3: Market Context - Semaglutide is currently a leading GLP-1 receptor agonist, with combined sales of approximately 84 billion USD in the first quarter of this year [3] - Tirzepatide, approved as the first GIP/GLP-1 receptor agonist in China, achieved sales of 6.15 billion USD in the first quarter, showing significant year-over-year growth [3]

Core Viewpoint - Eli Lilly announced detailed results from the SURMOUNT-5 study, demonstrating the efficacy and safety of tirzepatide compared to semaglutide in overweight adults with obesity and at least one comorbidity [1] Group 1: Study Overview - The SURMOUNT-5 study is an open-label Phase 3b clinical trial [1] - The trial aimed to evaluate the effectiveness of the GLP/GLP-1 dual receptor agonist tirzepatide against the GLP-1 single receptor agonist semaglutide [1] - Participants included overweight adults with obesity and at least one comorbidity, excluding those with diabetes [1] Group 2: Results - At week 72, tirzepatide achieved the primary endpoint and all five key secondary endpoints [1] - Throughout the trial, tirzepatide demonstrated superiority over semaglutide [1]